InsiderSignal.AI

InsiderSignal.ai

TVTX - Travere Therapeutics, Inc.

Insider Sale by Heerma Peter (Chief Commercial Officer)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

2 days ago, Heerma Peter, serving as Chief Commercial Officer at Travere Therapeutics, Inc. (TVTX), sold 7,215 shares at $41.93 per share, for a total transaction value of $302,516.00. Following this transaction, Heerma Peter now holds 138,608 shares of TVTX.

This sale represents a 5.00% decrease in Heerma Peter's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Tuesday, April 14, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, April 15, 2026, 1 day after the trade was made.

Travere Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Heerma Peter

Chief Commercial Officer

Peter Heerma is the Chief Commercial Officer at Travere Therapeutics, Inc. (NASDAQ: TVTX), a position he has held since October 2019.[[1]](https://travere.com/our-company/leadership-and-board/peter-heerma/)[[2]](https://fintool.com/app/research/companies/TVTX/people/peter-heerma)[[3]](https://ir.travere.com/press-releases/news-details/2019/Retrophin-Announces-Appointment-of-Peter-Heerma-as-Chief-Commercial-Officer-10-01-2019/default.aspx) In this role, he leads the company's commercial organization, overseeing commercialization strategy for approved products like FILSPARI and pre-commercial planning for pipeline programs, contributing to significant net product sales growth from $127.5 million in 2023 to $226.7 million in 2024.[[1]](https://travere.com/our-company/leadership-and-board/peter-heerma/)[[2]](https://fintool.com/app/research/companies/TVTX/people/peter-heerma) Heerma brings over 20 years of experience in biopharmaceuticals, including his prior role as Global Product General Manager for oncology and cardiovascular products at Amgen (2015–2019), where he managed portfolios exceeding $7 billion in revenue, and various leadership positions at AbbVie and Abbott Laboratories in areas such as portfolio strategy, renal care, and neuroscience.[[1]](https://travere.com/our-company/leadership-and-board/peter-heerma/)[[2]](https://fintool.com/app/research/companies/TVTX/people/peter-heerma) He holds a Master of Science in European business administration and business law from Lund University (Sweden) and a Bachelor of Science in retail management and marketing from Stenden University (Netherlands).[[1]](https://travere.com/our-company/leadership-and-board/peter-heerma/)[[2]](https://fintool.com/app/research/companies/TVTX/people/peter-heerma) Recently, as a corporate insider, he sold 4,980 shares of TVTX stock on December 24, 2025, for $199,200.[[4]](https://www.sahmcapital.com/news/content/travere-therapeutics-chief-commercial-officer-peter-heerma-reports-sale-of-common-shares-2025-12-30)[[6]](https://www.investing.com/news/insider-trading-news/heerma-travere-therapeutics-cco-sells-199k-in-tvtx-stock-93CH-4424854)

View full insider profile →

Trade Price

$41.93

Quantity

7,215

Total Value

$302,516.00

Shares Owned

138,608

Trade Date

Tuesday, April 14, 2026

2 days ago

SEC Filing Date

Wednesday, April 15, 2026

Filed 1 day after trade

HEALTHCAREBIOTECHNOLOGY

About Travere Therapeutics, Inc.

Company Overview

No company information available
View news mentioning TVTX

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5672343

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime